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The overexpression of P-glycoprotein (Pgp) is thought to be an
important mechanism of pharmacoresistance in epilepsy. Recently,
11C-phenytoin has been evaluated preclinically as a tracer for Pgp.
The aim of the present study was to assess the optimal plasma
kinetic model for quantiﬁcation of 11C-phenytoin studies in humans.
Methods: Dynamic 11C-phenytoin PET scans of 6 healthy volun-
teers with arterial sampling were acquired twice on the same day
and analyzed using single- and 2-tissue-compartment models with
and without a blood volume parameter. Global and regional test–
retest (TRT) variability was determined for both plasma to tissue rate
constant (K1) and volume of distribution (VT). Results: According to the
Akaike information criterion, the reversible single-tissue-compartment
model with blood volume parameter was the preferred plasma input
model. Mean TRT variability ranged from 1.5% to 16.9% for K1 and
from 0.5% to 5.8% for VT. Larger volumes of interest showed better
repeatabilities than smaller regions. A 45-min scan provided essentially
the same K1 and VT values as a 60-min scan. Conclusion: A reversible
single-tissue-compartment model with blood volume seems to be a
good candidate model for quantiﬁcation of dynamic 11C-phenytoin
studies. Scan duration may be reduced to 45 min without notable
loss of accuracy and precision of both K1 and VT, although this still
needs to be conﬁrmed under pathologic conditions.
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Epilepsy is one of the most common neurologic disorders world-
wide (1). Almost 30% of all patients who suffer from epilepsy do not
respond to drug therapy (2). Nonresponse may be related to an over-
expression of P-glycoprotein (Pgp). Pgp (3–5) is an efﬂux transporter,
located at the blood–brain barrier, that transports substrates (including
multiple central nervous system drugs) from the brain back into the
blood and cerebrospinal ﬂuid. The overexpression of Pgp is thought
to be an important mechanism of pharmacoresistance in epilepsy
(6,7). In refractory patients, this overexpression has been conﬁrmed
by examining brain tissue postmortem or after surgical removal (8,9).
The development of noninvasive imaging methods that would allow
for in vivo assessment of Pgp function in the brain is of great interest.
Several studies have demonstrated that PET with 11C-radiolabeled
Pgp substrates, such as (R)-11C-verapamil (3–5) or 11C-N-desmethyl-
loperamide (11C-dLop) (10), is a promising imaging tool for in vivo
assessment of Pgp function in the blood–brain barrier (7,11–13).
Other tracers to measure Pgp expression, such as 11C-laniquidar
(14,15) and 11C-tariquidar (16), have also been developed. These
compounds are inhibitors at pharmacologic doses but act as sub-
strates at tracer doses, and more work is needed to assess the
utility of these tracers. High-afﬁnity Pgp substrates have low brain
uptake, limiting their suitability as a PET tracer for mapping re-
gional Pgp overexpression, as this overexpression would reduce
uptake even further. 11C-phenytoin, an antiepileptic drug, is a rela-
tively weak Pgp substrate that is expected to show higher brain up-
take, possibly resulting in PET images with better image quality. The
slower washout and the fairly good stability of the tracer in plasma (as
shown later) might allow for robust kinetic evaluations. The purpose
of the present study was to identify a candidate model that may be
used for kinetic evaluations (17). To assess Pgp in patients with
pharmacoresistant epilepsy, a reliable quantiﬁcation method for
11C-phenytoin needs to be developed. The aim of the present study
was therefore to identify a potential candidate plasma input kinetic
model that may be used for the quantiﬁcation of 11C-phenytoin stud-
ies in humans and to establish its test–retest (TRT) performance.
MATERIALS AND METHODS
Subjects
Six healthy male volunteers (mean age, 28 y; age range, 21–32 y)
were included. All subjects were extensively screened for medical
history and underwent physical (including neurologic) examination
and laboratory tests. Subjects were also screened for neurologic and
psychiatric illness and history of drug abuse. Written informed con-
sent was obtained from each subject after each was given a written and
verbal description of the study. The study was approved by the Med-
ical Ethics Review Committee of the VU University Medical Center.
Imaging Procedure
All subjects underwent 2 identical dynamic PET studies on the
same day. Scans were performed on a Gemini TF PET/CT scanner
(Philips). The properties of this scanner have been reported elsewhere
(18). Before tracer injection, a low-dose CT scan was obtained. These
data were used to correct the subsequent emission scan for photon
attenuation. Next, a dynamic emission scan in 3-dimensional acquisi-
tion mode was started simultaneously with an intravenous injection of
345 6 54 (mean 6 SD) MBq of 11C-phenytoin with a speciﬁc activity
of 726 27 MBqmmol21. 11C-phenytoin was synthesized as described
previously (17). The radiotracer was provided in a total volume of
7 mL and administered at a rate of 0.8 mLs21, followed by a ﬂush of
42 mL of saline at 2.0 mLs21 using an infusion pump (Med-Rad).
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The scan was acquired in list-mode for 60 min. The list-mode data were
later histogrammed into 20 frames with progressive increase in frame
durations of 1 · 15, 3 · 5, 3 · 10, 4 · 60, 2 · 150, 2 · 300, and 4 · 600 s.
During acquisition, patient movement was restricted by the use of
a head holder and monitored by checking the position of the head using
laser beams. All emission data were reconstructed using a line-of-
response row-action maximum-likelihood algorithm, as provided by the
scanner vendor. All corrections required for generating quantitative PET
images, such as dead time, scatter, random, decay, and attenuation
corrections, were applied. The image matrix size was 128 · 128 with
90 axial slices, resulting in a voxel size of 2 · 2 · 2 mm. The recon-
structed spatial resolution was approximately 5 mm in full width at
half maximum at the center of the ﬁeld of view. After image recon-
struction, patient motion (which may have occurred despite the use of
the head holder) was assessed and corrected by a frame-by-frame
alignment of the images using VINCI software (Max Plank Institute).
During the 60-min 11C-phenytoin scan, arterial blood was with-
drawn continuously using an automatic online blood sampler (Veenstra
Instruments) (19) at a rate of 5 mLmin21 for
the ﬁrst 5 min and 2.5 mLmin21 thereafter.
At 2.5, 5, 10, 20, 30, 40, and 60 min after
tracer injection, continuous blood sampling
was interrupted brieﬂy to withdraw 7 mL of
manual blood samples. After each sample,
the arterial line was ﬂushed with a heparin-
ized saline solution. In addition, all sub-
jects underwent structural MR imaging using
a 1.5-T Sonata scanner (Siemens Medical
Solutions).
Blood Analysis
Manual samples were used to determine
plasma–to–whole-blood radioactivity con-
centration ratios. In addition, concentrations
of parent 11C-phenytoin and its radioactive
metabolites in plasma were determined using
the following procedure. One milliliter of
plasma was diluted with 2 mL of water and
passed over an activated Sep-Pak tC18
(Waters). After being rinsed with 3 mL of
water, the cartridge was eluted with 1.5 mL
of methanol and 1.5 mL of water. This eluate
was vortexed and analyzed further using
high-performance liquid chromatography
(HPLC). The HPLC consisted of a Dionex Ultimate 3000, equipped
with a 1.0-mL loop. A Phenomenex (Torrance) Gemini C18 10 ·
250 mm 5-mm column was used. The mobile phase consisted of
a mixture of acetonitrile and 0.1% triﬂuoroacetic acid in water. During
analysis, a gradient was used so that the percentage of 0.1% triﬂuoro-
acetic acid in water was 90% at the start of analysis and 30% after
4 min. Flow of the mobile phase was 4.0 mLmin21.
Plasma–to–whole-blood ratios and parent fractions were used in
combination with the continuously collected whole-blood input curve
to generate a metabolite-corrected plasma input function. Hill func-
tions (20) were used to ﬁt parent fractions and plasma-to-blood ratios.
Image Analysis
First, each MR image was coregistered with the corresponding
PET image using VINCI software. Next, volumes of interest (VOIs)
were deﬁned using an automated method based on a VOI template
(PVElab) (21) that consisted of 67 regions covering the entire brain
(22). Gray and white matter segmentation of the coregistered MR
FIGURE 1. Typical 11C-phenytoin activity concentration images obtained in healthy subject,
averaged over several early frames (30–90 s after injection) (A) and late frames (45–60 min after
injection) (B).
FIGURE 2. Example of decay-corrected time–activity curves of 11C-
phenytoin for several brain regions in healthy subject.
FIGURE 3. Mean and SD (error bar) of parent and polar fractions,
plasma–to–whole-blood ratio (P/WB), and HPLC metabolites obtained
from manual blood samples.
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image was performed using statistical parametric mapping (version 8,
SPM8), which is incorporated in the PVElab software. Finally, gray
matter time–activity curves were generated by projecting all VOIs onto
the dynamic PET data.
Kinetic Analysis
Various compartment models were tested (23), such as plasma-
input single-tissue-compartment models without (1T2k) and with
(1T2k 1 Vb) blood volume parameter, and plasma-input 2-tissue-
compartment models with irreversible (2T3k) and reversible (2T4k)
kinetics, both with and without additional Vb. In addition, 1T2k,
2T3k, and 2T4k models with Vb ﬁxed to 5% were tested as well.
Models were ﬁtted to gray matter time–activity curves using stan-
dard nonlinear regression analysis. Fitting routines were developed in-
house using Matlab software (The MathWorks). For each of the ﬁts,
the Akaike information criterion (AIC) (24) was calculated. For each
time–activity curve, the preferred model was selected on the basis of
the lowest AIC across all models. The frequency of AIC preferences
for each model (pooled over all subjects) was then derived, and the
model with the highest overall frequency was selected as the preferred
model. Model preferences were evaluated separately for both small
(#5 mL) and large (.5 mL) VOIs. In addition, an F test (25) was
used to assess whether models with more kinetic parameters were
preferred over those with fewer. Finally, kinetic analysis was re-
peated for shorter scan intervals to investigate the impact of scan
duration on model preference and parameter estimates and to ob-
tain an estimate of the minimally required scan duration for reli-
able quantiﬁcation.
TRT Variability
After kinetic analysis, TRT variability of all kinetic parameters was
calculated. TRT variability was calculated as the difference between test and
retest kinetic parameters divided by their mean times 100%. The Student t
test was used to assess the impact of different scan durations and VOI size
on TRTof the plasma to tissue rate constant (K1) and volume of distribution
(VT). Moreover, Bland–Altman plots (26) of the kinetic parameters
were generated to illustrate differences between test and retest values.
RESULTS
PET Image and Blood Data Analysis
A typical 11C-phenytoin uptake image, averaged over the
frames collected from 25 to 90 s after injection and averaged over
frames from 45 to 60 min after injection are shown in Figure 1,
illustrating the distribution of 11C-phenytoin uptake at different
uptake intervals throughout the brain. Time–activity curves for
several regions of interest are shown in Figure 2. Various ﬁts for
the whole-brain gray matter time–activity curve are shown in
Supplemental Figure 1 (supplemental materials are available at
http://jnm.snmjournals.org). Average plasma–to–whole-blood ra-
tios, parent fractions, and polar and nonpolar metabolite fractions
are presented in Figure 3. The plasma–to–
whole-blood ratio was relatively constant
over time, ranging from about 1.3 to 1.4.
The parent fraction of 11C-phenytoin in
plasma slowly decreased to 79% 6 4% at
60 min, whereas nonpolar and polar me-
tabolite fractions increased from 2.3% 6
2.1% and 2.1% 6 1.8% at 2.5 min to
16.1% 6 3.1% and 4.4% 6 2.2% at
60 min, respectively. At present, these ra-
diolabeled metabolites have not yet been
characterized.
Compartmental Modeling
Four of the 6 compartment models ﬁtted
both test and retest data well. AIC pref-
erence percentages are shown in Table 1
for both test and retest scans. As can be
seen, the 1T2k 1 Vb model was preferred
in most cases, followed by 2T3k1 Vb and
2T4k 1 Vb models. This preference was
TABLE 1
Preference Frequency (%) According to Akaike Information
Criteria for Small (,5 mL) and Large (.5 mL) VOI Sizes
Akaike frequency (%)
Model VOI , 5 mL VOI . 5 mL
1T2k 0.0 0.0
1T2k 1 Vb 31.3 42.2
2T3k 0.0 0.0
2T3k 1 Vb 4.6 13.8
2T4k 0.0 0.0
2T4k 1 Vb 4.9 3.2
FIGURE 4. TRT variability of K1 (A) and VT (B) for each subject for small (,5 mL) and large
(.5 mL) region-of-interest volumes.
TABLE 2
TRT Variabilities for K1 and VT for Each Individual Subject,
Given as Average (±SD) Percentage Repeatability Across All
VOIs
Subject K1 TRT VT TRT
1 4.10 ± 4.72 2.23 ± 4.62
2 0.83 ± 5.98 −3.15 ± 6.95
3 8.76 ± 4.50 1.53 ± 6.01
4 −6.13 ± 7.71 −3.42 ± 6.78
5 −17.6 ± 7.24 −2.99 ± 13.8
6 6.51 ± 4.44 −2.46 ± 3.70
Average ± SD −0.59 ± 10.73 −1.38 ± 8.00
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seen regardless of the volume of the VOIs as shown in Table 1.
A Vb was required for all models tested. This model was pre-
ferred across all subjects studied for each individual region—
that is, we could not identify a speciﬁc region with a different
preference. Although models with a ﬁxed blood volume frac-
tion of 5% were also evaluated, the 1T2k 1 Vb model using Vb
as ﬁt parameter was still preferred. AIC preferences were con-
ﬁrmed by F test scores that showed that for more than 60% of
the time–activity curve the simpler model (1T2k 1 Vb) was
favored over more complicated ones. In Supplemental Figure
2, K1 and VT data are given for various regions across the brain.
As can be seen, K1 and VT values are reasonably comparable
across the gray matter regions shown and correspond to the
distributions seen in the early and late uptake images shown in
Figure 1.
TRT Repeatability
Figure 4 shows box plots of percentage differences between
test and retest scans for K1 and VT values, respectively,
obtained using the 1T2k 1 Vb model. Results are provided
per patient for both small (#5 mL) and large (.5 mL) VOIs.
In general, the median percentage differences between test and
retest studies were about 10%, except for subject 5 who showed
up to 20% of TRT variability for K1 (Fig. 4A). A somewhat
wider range (larger interquartile range) in TRT variability of
both K1 and VT (Fig. 4B) was observed for small compared with
large VOIs, but this difference is not statistically signiﬁcant
(t test, P . 0.05). Individual TRT variabilities are provided in
Table 2.
Impact of Scan Duration
Supplemental Figure 3 shows fair to good correlations of 1T2k1
Vb–derived K1 and VT values for shorter scan durations (45 and
30 min) with those obtained for 60-min scans. In the case of K1,
the correlation was slightly better for 45- than for 30-min data for
both test and retest scans (Supplemental Figs. 3A and 3B). The
same was true for VT, although the difference between 45 and
30 min was larger (Supplemental Figs. 3C and 3D). Although
there were fair to good correlations between 45- and 30-min data
and those of 60 min, a signiﬁcant difference in the correlation of
VT was seen when the scan duration was reduced to 30 min (P ,
0.05). Table 3 shows the summary information of correlation
between different scan durations.
TRT data are shown as Bland–Altman plots in Figure 5, and
percentage TRT repeatability for individual patients is shown in
Figure 6 for both K1 (Fig. 6A) and VT (Fig. 6B). It can be seen that
shortening the scan duration from 60 to 45 min did not substan-
tially affect the TRT variability of K1 and VT.
DISCUSSION
Compared with previous preclinical studies in rats (17), the me-
tabolism of 11C-phenytoin in humans was relatively slow, with 79%
of the original tracer still intact at 60 min after injection. The parent
fraction was higher than that of other, more avid Pgp substrates,
such as (R)-11C-verapamil, with 50% intact parent tracer at 60 min
(27). In addition, parent fractions of 11C-phenytoin were compara-
ble across subjects, as indicated by the small variability (SD) shown
in Figure 3. This small intersubject variability and the slow meta-
bolism of 11C-phenytoin may allow for the use of a plasma input
function without additional metabolite analysis, for example, using
a population average approach for the parent fraction. However, this
approach was not (yet) evaluated because of the small number of
subjects and it should also be noted that 11C-phenytoin metabolism
may be affected by treatment or be different in patients. Variability
in tracer metabolism ﬁrst needs to be investigated under these con-
ditions before population-based approaches can be used. Neverthe-
less, 11C-phenytoin seems to have a favorable metabolic proﬁle.
In this study, we evaluated a possible suitable candidate model
to analyze 11C-phenytoin kinetics. Among various models inves-
tigated, the single-tissue-compartment model with 2 kinetic
parameters and an additional blood volume fraction parameter
was the preferred plasma input model in 60%–70% of cases (Table 1).
Moreover, this model was preferred
across all subjects studied for each individ-
ual region, and it is therefore the model of
choice for quantiﬁcation of dynamic 11C-
phenytoin studies. The preference for the
1T2k 1 Vb model was more pronounced
than in the case of (R)-11C-verapamil,
where it was preferred in only 15% of the
cases (27). The preference for a model with
a limited number of ﬁt parameters in com-
bination with slow tracer metabolism in
plasma suggests that robust quantiﬁcation of
11C-phenytoin studies is feasible. Feasibility
was conﬁrmed by the observed good TRT
performances, as discussed later.
The present study was performed to
identify a possible suitable candidate plasma
input kinetic model for 11C-phenytoin and,
TABLE 3
Summary of Correlation Parameters Between Data from
Different Scan Durations (45 and 30 Minutes) Versus 60
Minutes
K1 VT
Test Retest Test Retest
Scan duration Slope R2 Slope R2 Slope R2 Slope R2
45 vs. 60 min 1.00 0.98 1.00 0.98 1.00 0.84 1.00 0.90
30 vs. 60 min 1.02 0.97 1.00 0.98 0.98 0.76 0.99 0.86
FIGURE 5. Bland–Altman plots of K1 (A–C) and VT (D–F) test–retest data for 60- (A and D), 45- (B and
E), and 30- (C and F) min scan durations. s 5 60-min scan duration data; h 5 45-min scan duration
data; 4 5 30-min scan duration data; bold line 5 mean difference between test and retest.
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subsequently, to test its performance with respect to repeatability
using test and retest scans in healthy subjects. In general, TRT re-
peatability of K1 and VT was small—that is, on average within
10%—and comparable with that seen for (R)-11C-verapamil
(27). TRT of K1 of subject 5, however, equaled about 17%. This
particular case could be explained by a lower parent fraction dur-
ing the initial part (5 min) of the PET scan for only 1 of the scans.
When the parent fraction was set to a higher value (i.e., equal to
the average of all other subjects), TRT variability improved to
within 10%. The observed poor K1 TRT of about 17% of this
subject seems therefore to be caused by a measurement error in
the parent fraction. Larger regions of interest (.5 mL) showed
a smaller interquartile range for TRT than smaller regions of interest,
but this difference was not signiﬁcant (t test, P . 0.05). Because
compartmental model analysis is sensitive to noise, an increase in
TRT can be expected when using smaller regions of interest.
Reducing the scan duration to 45 or 30 min resulted in VT
estimates that were similar to those obtained from the entire
60 min of data, with somewhat higher correlation coefﬁcients
for the 45-min data (Figs. 6C and 6D). In addition, for none of
the subjects TRT performances of both K1 and VT were substan-
tially affected by changing scan duration. However, there was
a signiﬁcant difference in VT TRT (P , 0.05) for 30- versus
60-min data. Yet, TRT variability was, on average, less than
10% for both VT and K1 in most subjects.
It can be concluded that 11C-phenytoin
dynamic PET studies in healthy subjects
can be performed using 45-min scan dura-
tions without signiﬁcantly affecting accu-
racy and TRT performance of both K1 and
VT estimates. However, for patients and
for studies after pharmacologic blocking
of Pgp or during treatment, the washout
of 11C-phenytoin may be reduced or tracer
metabolism might be different and longer
scan durations may still be required, which
need to be clariﬁed in future studies.
Results of this ﬁrst-in-human PET study
showed good agreement with observations
of a previous preclinical study (17). In par-
ticular, the present study conﬁrmed good
tracer characteristics of 11C-phenytoin—
that is, high metabolic stability in plasma
and robust kinetics, with a maximum brain
uptake approximately 20 min after bolus
injection. Results from the present study also indicate that 11C-
phenytoin has slower ingrowth of labeled metabolites in plasma
and a higher VT than (R)-11C-verapamil (28). K1 was similar to
that of (R)-11C-verapamil and 3-fold higher than that of 11C-dLop
(10). In addition, the efﬂux rate (k2) of 11C-phenytoin was approx-
imately 60% lower than that of (R)-11C-verapamil (28) and about
4-fold higher than that of 11C-dLop. However, k2 values of the
various tracers cannot be directly compared with each other be-
cause of the use of different kinetic models. VT of 11C-phenytoin
was found to be approximately 25% lower than that of 11C-dLop
and 30% higher than that of (R)-11C-verapamil. The distribution of
VT of 11C-phenytoin was fairly uniform across the various gray
matter brain regions and comparable to that seen with (R)-11C-
verapamil. A summary of various kinetic parameters is presented
in Table 4. Among the 3 presented tracers, 11C-phenytoin seems to
demonstrate a high ﬁrst-pass extraction fraction (by the fairly high
K1 values), resulting in high tracer brain uptake and intermediate-
high VT, because of the low k2 values, and low plasma metabo-
lism, which might explain the robust kinetic analysis and good
TRT performances seen so far.
In the present study the kinetic properties of 11C-phenytoin were
assessed, and a possible suitable candidate model for quantitative
analysis was established. Nevertheless, further studies will be
needed to assess whether 11C-phenytoin is a useful tracer and
whether the preferred candidate model is suitable for investigating
FIGURE 6. TRT variability of K1 (A) and VT (B) for each subject and for different scan durations.
TABLE 4
Comparison of Some Kinetic Parameters for 11C-Phenytoin, (R)-11C-Verapamil, and 11C-dLop
Pgp substrate K1 (mLmL−1min−1) k2 (min−1) VT (mLmL−1)
11C-phenytoin (n 5 6)*† 0.037 ± 0.008 0.042 ± 0.009 0.881 ± 0.126
(R)-11C-verapamil (n 5 5)‡ 0.036 ± 0.009 0.102 ± 0.003 0.660 ± 0.123
11C-dLop (n 5 6)* 0.014 ± 0.001 0.012 ± 0.002 1.169 ± 0.149
*Obtained using 1T2k 1 Vb model.
†Pooled over whole-brain region across all subjects.
‡Obtained using 2T4k model.
Data are mean ± SD.
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Pgp function under pathologic conditions. Moreover, PET studies
using a Pgp inhibitor, such as with high doses of laniquidar or
tariquidar, could be performed to assess whether 11C-phenytoin
PET can measure and quantify changes in Pgp function. The TRT
data from the present study will be of relevance for interpretation of
those intervention studies.
CONCLUSION
11C-phenytoin kinetics seem to be well represented by a
plasma-input, single-tissue-compartment model with an additional
ﬁtted blood volume fraction parameter. Yet, this ﬁnding remains to
be veriﬁed under pathologic conditions. 11C-phenytoin is stable in
plasma, with about 80% of intact tracer at 1 h after injection. Scan
durations can be reduced to 45 min without notable loss in accu-
racy and precision, although this needs to be validated under patho-
logic conditions or during treatment. Observed TRT performances
for K1 and VT are comparable to those seen with various other
tracers (,10%, on average).
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